In a significant development, an advisory panel of the U.S. Food and Drug Administration (FDA) has backed AstraZeneca’s prostate cancer combination therapy in a key vote, strengthening its chances of regulatory approval and offering new hope for patients with advanced disease.
The FDA’s Oncologic Drugs Advisory Committee voted 7–1, with one abstention, in favour of the treatment, citing a strong benefit–risk profile and supporting a new prostate cancer treatment approach. The therapy combines Truqap (capivasertib) with abiraterone and androgen deprivation therapy (ADT).
The panel’s recommendation was largely based on findings from the Phase III CAPItello-281 trial, which showed clear clinical benefits in metastatic hormone-sensitive prostate cancer (mHSPC). The data highlighted improved radiographic progression-free survival and reduced risk of disease progression or death.
Medical experts have pointed out that PTEN-deficient prostate cancer tends to be more aggressive, reinforcing the importance of targeted cancer therapy in improving patient outcomes. The positive vote reflects growing confidence in AstraZeneca’s treatment strategy.
Also Read: OneSource Partners Secure Canada Nod for Generic Semaglutide
Although the FDA is not required to follow the advisory panel’s recommendation, such decisions usually carry considerable influence on FDA approval decisions and the broader drug regulatory process. A strong majority vote often signals a higher likelihood of approval.
The endorsement comes at a time when AstraZeneca’s oncology pipeline faces scrutiny, especially in oncology drug development and clinical trial evaluation. The panel did not support one of its experimental breast cancer drugs during the same meeting.
Still, this positive outcome marks an important step forward for advanced prostate cancer patients and highlights progress in innovative cancer treatments. If approved, the therapy could expand options and improve survival prospects globally.
.jpg)
.jpg)
